Research programme: CTLA-4/FasL fusion protein - KAHR Medical

Drug Profile

Research programme: CTLA-4/FasL fusion protein - KAHR Medical

Alternative Names: KAHR-102

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KAHR Medical
  • Class Proteins
  • Mechanism of Action Apoptosis stimulants; CD80 antigen inhibitors; CD86 antigen inhibitors; CD95 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Israel (SC)
  • 08 Mar 2017 KAHR Medical suspends patient enrolment due to delay in IP production in a phase I/IIa trial for Lymphoma (Second-line therapy or greater) in Israel (SC) (NCT02545361)
  • 15 Dec 2015 KAHR Medical receives regulatory approval in Israel for the initiation of a phase I/II trial before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top